100) Drug Policy
America has faced four major drug epidemics, and many argue we're in another epidemic today. Today I spoke with Dr. Beau Kilmer about his research surrounding the problems, and possible solutions to our drug issues.
Bio: Beau Kilmer (he/him) is the McCauley Chair in Drug Policy Innovation, director of the RAND Drug Policy Research Center, and a senior policy researcher at the RAND Corporation. His research lies at the intersection of public health and public safety, with special emphasis on crime control, substance use, illegal markets, and public policy.
Some of his current projects include analyzing the consequences of cannabis legalization (with a special focus on social equity); measuring the effect of 24/7 Sobriety programs on DUI, domestic violence, and mortality; facilitating San Francisco's Street-Level Drug Dealing Task Force; and evaluating the evidence and arguments made about implementing heroin-assisted treatment and supervised consumption sites.
Kilmer's publications have appeared in leading journals such as New England Journal of Medicine and Proceedings of the National Academy of Sciences, and his commentaries have been published by CNN, Los Angeles Times, New York Times, San Francisco Chronicle, USA Today, Wall Street Journal, and other outlets. His coauthored book on cannabis legalization was published by Oxford University Press and his coauthored book on the future of fentanyl and other synthetic opioids was published by RAND.
Kilmer received a NHTSA Public Service Award for his "leadership and innovation in the areas of alcohol and drug-impaired driving program and policy research" and his coauthored work on 24/7 Sobriety received honourable mention for the Behavioural Exchange Award for Outstanding Research. He received his Ph.D. in public policy from Harvard University, M.P.P. from UC Berkeley, and B.A. in international relations from Michigan State University.
Twitter - https://twitter.com/BeauKilmer